Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

249
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
249
Activation of Integrins01:15

Activation of Integrins

3.6K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

223
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
223
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

258
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
258
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.9K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

8.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NfL makes regulatory debut as neurodegenerative disease biomarker.

Nature reviews. Drug discovery·2023
Same author

NCATS's plan to grow the rare disease pipeline.

Nature reviews. Drug discovery·2023
Same author

GSK buys purine receptor antagonist for $2 billion.

Nature reviews. Drug discovery·2023
Same author

FDA approves second microbiome-based C. difficile therapy.

Nature reviews. Drug discovery·2023
Same author

Astellas buys complement inhibitor for $5.9 billion.

Nature reviews. Drug discovery·2023
Same author

Setting GPCRs free.

Nature reviews. Drug discovery·2023

Related Experiment Video

Updated: Sep 2, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

520

Pliant's integrin inhibitor boosted by phase II IPF data

Asher Mullard

    Nature Reviews. Drug Discovery
    |August 5, 2022
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
    04:15

    Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

    Published on: February 2, 2024

    1.9K
    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
    08:45

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

    Published on: July 17, 2020

    6.3K

    Related Experiment Videos

    Last Updated: Sep 2, 2025

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    520
    Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
    04:15

    Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

    Published on: February 2, 2024

    1.9K
    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
    08:45

    Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

    Published on: July 17, 2020

    6.3K